Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

SELL
$18.65 - $26.52 $484,489 - $688,936
-25,978 Reduced 19.42%
107,774 $2.39 Million
Q4 2023

Feb 02, 2024

BUY
$16.53 - $21.42 $386,785 - $501,206
23,399 Added 21.2%
133,752 $2.84 Million
Q3 2023

Nov 08, 2023

BUY
$20.08 - $25.39 $440,675 - $557,208
21,946 Added 24.82%
110,353 $2.22 Million
Q2 2023

Aug 02, 2023

BUY
$24.77 - $29.9 $509,915 - $615,521
20,586 Added 30.35%
88,407 $2.21 Million
Q1 2023

Apr 26, 2023

SELL
$25.95 - $36.95 $381,724 - $543,534
-14,710 Reduced 17.82%
67,821 $1.89 Million
Q3 2022

Oct 28, 2022

SELL
$24.62 - $32.44 $343,005 - $451,954
-13,932 Reduced 14.44%
82,531 $2.14 Million
Q2 2022

Aug 04, 2022

BUY
$19.74 - $29.01 $400,050 - $587,916
20,266 Added 26.6%
96,463 $2.64 Million
Q4 2021

Jan 31, 2022

SELL
$33.67 - $43.44 $321,043 - $414,200
-9,535 Reduced 11.12%
76,197 $3.06 Million
Q3 2021

Oct 27, 2021

BUY
$30.65 - $35.68 $737,193 - $858,175
24,052 Added 38.99%
85,732 $2.8 Million
Q2 2021

Jul 23, 2021

BUY
$34.33 - $44.68 $560,299 - $729,222
16,321 Added 35.98%
61,680 $2.13 Million
Q1 2021

Apr 27, 2021

SELL
$40.81 - $53.88 $326,602 - $431,201
-8,003 Reduced 15.0%
45,359 $1.95 Million
Q4 2020

Feb 03, 2021

SELL
$36.63 - $47.63 $346,812 - $450,960
-9,468 Reduced 15.07%
53,362 $2.33 Million
Q3 2020

Oct 27, 2020

BUY
$30.09 - $43.02 $66,348 - $94,859
2,205 Added 3.64%
62,830 $2.44 Million
Q2 2020

Aug 04, 2020

SELL
$27.76 - $33.42 $61,932 - $74,560
-2,231 Reduced 3.55%
60,625 $1.96 Million
Q4 2019

Jan 31, 2020

BUY
$32.75 - $41.43 $362,084 - $458,050
11,056 Added 21.34%
62,856 $2.16 Million
Q3 2019

Oct 23, 2019

BUY
$33.73 - $46.27 $1.75 Million - $2.4 Million
51,800 New
51,800 $1.75 Million

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.41B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track State Of New Jersey Common Pension Fund D Portfolio

Follow State Of New Jersey Common Pension Fund D and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of New Jersey Common Pension Fund D, based on Form 13F filings with the SEC.

News

Stay updated on State Of New Jersey Common Pension Fund D with notifications on news.